• 1
    Horny HP,Metcalfe DD,Bennett JM, et al. Mastocytosis. In: SwerdlowSH,CampoE,HarrisNL, et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: International Agency for Research and Cancer (IARC); 2008. pp 5463.
  • 2
    Brunning RD,McKenna RW,Rosai J, et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol 1983; 7: 425438.
  • 3
    Horny HP,Parwaresch MR,Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985; 16: 808814.
  • 4
    Stevens EC,Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol 2001; 116: 177182.
  • 5
    Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963; 87: 146157.
  • 6
    Uzzaman A,Maric I,Noel P, et al. Pediatric-onset mastocytosis: A long term clinical follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer 2009; 53: 629634.
  • 7
    Azana JM,Torrelo A,Mediero IG, et al. Urticaria pigmentosa: A review of 67 pediatric cases. Pediatr Dermatol 1994; 11: 102106.
  • 8
    Kettelhut BV,Metcalfe DD. Pediatric mastocytosis. Ann Allergy 1994; 73: 197202; quiz 202–207.
  • 9
    Lim KH,Tefferi A,Lasho, TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 2009; 113: 57275736.
  • 10
    Bain BJ,Gilliland DG,Horny HP, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: SwerdlowSH,CampoE,HarrisNL, et al., editors. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: International Agency for Research and Cancer (IARC); 2008. pp 6873.
  • 11
    Cools J,DeAngelo DJ,Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 12011214.
  • 12
    Klion AD,Noel P,Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 46604666.
  • 13
    Klion AD,Robyn J,Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473478.
  • 14
    Pardanani A,Brockman SR,Paternoster SF, et al. FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 30383045.
  • 15
    Pardanani A,Elliott M,Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535536.
  • 16
    Pardanani A,Ketterling RP,Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 30933096.
  • 17
    Dalal BI,Horsman DE,Bruyere H, et al. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation. Am J Hematol 2007; 82: 7779.
  • 18
    Walz C,Metzgeroth G,Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007; 92: 163169.
  • 19
    Horny HP,Sotlar K,Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol 2004; 57: 604608.
  • 20
    Sotlar K,Fridrich C,Mall A, et al. Detection of c-kit point mutation Asp-816[RIGHTWARDS ARROW]Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002; 26: 979984.
  • 21
    Travis WD,Li CY,Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988; 62: 965972.
  • 22
    Pardanani A,Lim KH,Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009; 114: 37693772.
  • 23
    Pardanani A,Reeder T,Li CY, et al. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res 2003; 27: 883885.
  • 24
    Taylor ML,Sehgal D,Raffeld M, et al. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004; 6: 335342.
  • 25
    Tefferi A,Lasho TL,Brockman SR, et al. FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004; 89: 871873.
  • 26
    Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med 2005; 129: 219222.
  • 27
    Yarden Y,Kuang WJ,Yang-Feng T, et al. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 33413351.
  • 28
    Miettinen M,Lasota J. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005; 13: 205220.
  • 29
    Valent P,Spanblochl E,Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992; 80: 22372245.
  • 30
    Garcia-Montero AC,Jara-Acevedo M,Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 23662372.
  • 31
    Buttner C,Henz BM,Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 1998; 111: 12271231.
  • 32
    Furitsu T,Tsujimura T,Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 17361744.
  • 33
    Sotlar K,Escribano L,Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737746.
  • 34
    Beghini A,Cairoli R,Morra E, et al. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation. Blood Cells Mol Dis 1998; 24: 262270.
  • 35
    Longley BJJr.,Metcalfe DD,Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 16091614.
  • 36
    Pullarkat VA,Pullarkat ST,Calverley DC, et al. Mast cell disease associated with acute myeloid leukemia: Detection of a new c-kit mutation Asp816His. Am J Hematol 2000; 65: 307309.
  • 37
    Pignon JM,Giraudier S,Duquesnoy P, et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997; 96: 374376.
  • 38
    Bodemer C,Hermine O,Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130: 804815.
  • 39
    Yanagihori H,Oyama N,Nakamura K, et al. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn 2005; 7: 252257.
  • 40
    Verzijl A,Heide R,Oranje AP, et al. C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Dermatology 2007; 214: 1520.
  • 41
    Gari M,Goodeve A,Wilson G, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999; 105: 894900.
  • 42
    Lux ML,Rubin BP,Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156: 791795.
  • 43
    Goemans BF,Zwaan CM,Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19: 15361542.
  • 44
    Hartmann K,Wardelmann E,Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005; 129: 10421046.
  • 45
    Zhang LY,Smith ML,Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006; 30: 373378.
  • 46
    Akin C,Fumo G,Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 32223225.
  • 47
    Tang X,Boxer M,Drummond A, et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004; 41: e88.
  • 48
    Zappulla JP,Dubreuil P,Desbois S, et al . Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med 2005; 202: 16351641.
  • 49
    Gerbaulet A,Wickenhauser C,Scholten J, et al. Mast cell hyperplasia, B cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 2011; 117: 20122021.
  • 50
    Tefferi A,Levine RL,Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900904.
  • 51
    Wilson TM,Maric I,Simakova O, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2010 Dec 6. [Epub ahead of print].
  • 52
    Guo X,Schrader KA,Xu Y, et al. Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras. Oncogene 2005; 24: 23302342.
  • 53
    Horny HP,Sillaber C,Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998; 22: 11321140.
  • 54
    Horny HP,Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002; 127: 115117.
  • 55
    Sotlar K,Horny HP,Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28: 13191325.
  • 56
    Jordan JH,Walchshofer S,Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: Evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001; 32: 545552.
  • 57
    Escribano L,Garcia Montero AC,Nunez R, et al. Flow cytometric analysis of normal and neoplastic mast cells: Role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006; 26: 535547.
  • 58
    Pardanani A,Kimlinger T,Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients. Leuk Res 2004; 28: 777783.
  • 59
    Galli SJ,Kalesnikoff J,Grimbaldeston MA, et al. Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annu Rev Immunol 2005; 23: 749786.
  • 60
    Sperr WR,El-Samahi A,Kundi M, et al. Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009; 39: 914923.
  • 61
    Pardanani A,Lim KH,Lasho TL, et al. WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010; 115: 150151.
  • 62
    Akin C. Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8: 412419.
  • 63
    Yavuz AS,Lipsky PS,Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002; 100: 661665.
  • 64
    Sotlar K,Colak S,Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 220: 586595.
  • 65
    Travis WD,Li CY,Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67: 345368.
  • 66
    Escribano L,Alvarez-Twose I,Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514521.
  • 67
    Nakamura R,Chakrabarti S,Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006; 37: 353358.
  • 68
    Valent P,Akin C,Escribano L, et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435453.
  • 69
    Pardanani A,Tefferi A. Proposal for a revised classification of systemic mastocytosis. Blood 2010; 115: 27202721.
  • 70
    Kluin-Nelemans HC,Jansen JH,Breukelman H, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med 1992; 326: 619623.
  • 71
    Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998; 138: 489495.
  • 72
    Butterfield JH,Tefferi A,Kozuh GF. Successful treatment of systemic mastocytosis with high-dose interferon-alfa: Long-term follow-up of a case. Leuk Res 2005; 29: 131134.
  • 73
    Kolde G,Sunderkotter C,Luger TA. Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol 1995; 133: 9194.
  • 74
    Lehmann T,Beyeler C,Lammle B, et al. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2B. Br J Rheumatol 1996; 35: 898900.
  • 75
    Lehmann T,Lammle B. IFNalpha treatment in systemic mastocytosis. Ann Hematol 1999; 78: 483484.
  • 76
    Takasaki Y,Tsukasaki K,Jubashi T, et al. Systemic mastocytosis with extensive polypoid lesions in the intestines; successful treatment with interferon-alpha. Intern Med 1998; 37: 484488.
  • 77
    Weide R,Ehlenz K,Lorenz W, et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996; 72: 4143.
  • 78
    Hauswirth AW,Simonitsch-Klupp I,Uffmann M, et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature. Leuk Res 2004; 28: 249257.
  • 79
    Lippert U,Henz BM. Long-term effect of interferon alpha treatment in mastocytosis. Br J Dermatol 1996; 134: 11641165.
  • 80
    Petit A,Pulik M,Gaulier A, et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical features and response to interferon alfa therapy. J Am Acad Dermatol 1995; 32: 850853.
  • 81
    Worobec AS,Kirshenbaum AS,Schwartz LB, et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996; 22: 501508.
  • 82
    Brunel V,Tadrist Z,Cailleres S, et al. [Interferon alpha and pamidronate: A useful combination in the treatment of osteoporosis and systemic mastocytosis]. Presse Med 1998; 27: 64.
  • 83
    Czarnetzki BM,Algermissen B,Jeep S, et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994; 30: 500501.
  • 84
    Hennessy B,Giles F,Cortes J, et al. Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. Am J Hematol 2004; 77: 209214.
  • 85
    Delaporte E,Pierard E,Wolthers BG, et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995; 132: 479482.
  • 86
    Lippert U,Henz BM. Long-term effect of interferon alpha treatment in mastocytosis.[comment]. Br J Dermatol 1996; 134: 11641165.
  • 87
    Lim KH,Pardanani A,Butterfield JH, et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84: 790794.
  • 88
    Simon J,Lortholary O,Caillat-Vigneron N, et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004; 52: 294299.
  • 89
    Bohm A,Sonneck K,Gleixner KV, et al. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38: 744755.
  • 90
    Gleixner KV,Mayerhofer M,Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752759.
  • 91
    Penack O,Sotlar K,Noack F, et al. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia. Ann Hematol 2005; 84: 692693.
  • 92
    Tefferi A,Li CY,Butterfield JH, et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307309.
  • 93
    Kluin-Nelemans HC,Oldhoff JM,Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 42704276.
  • 94
    Pardanani A,Hoffbrand AV,Butterfield JH, et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127131.
  • 95
    Hermine O,Hirsh I,Damaj G, et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 44 patients. In: American Society of Hematology Annual Meeting Abstracts.Blood, Orland, FL. December 4-7, 2010; 116: 1982.
  • 96
    Zermati Y,De Sepulveda P,Feger F, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22: 660664.
  • 97
    Akin C,Brockow K,D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003; 31: 686692.
  • 98
    Ma Y,Zeng S,Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 17411744.
  • 99
    Nakagomi N,Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007; 87: 365371.
  • 100
    Droogendijk HJ,Kluin-Nelemans HJ,van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial. Cancer 2006; 107: 345351.
  • 101
    Vega-Ruiz A,Cortes JE,Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33: 14811484.
  • 102
    Pagano L,Valentini CG,Caira M, et al. Advanced mast cell disease: An Italian Hematological Multicenter experience. Int J Hematol 2008; 88: 483488.
  • 103
    Schittenhelm MM,Shiraga S,Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473481.
  • 104
    Shah NP,Lee FY,Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286291.
  • 105
    Gleixner KV,Mayerhofer M,Sonneck K, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007; 92: 14511459.
  • 106
    Aichberger KJ,Sperr WR,Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008; 38: 869873.
  • 107
    Ustun C,Corless CL,Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res. 2009; 33: 735741.
  • 108
    Verstovsek S,Tefferi A,Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14: 39063915.
  • 109
    Purtill D,Cooney J,Sinniah R, et al. Dasatinib therapy for systemic mastocytosis: Four cases. Eur J Haematol 2008; 80: 456458.
  • 110
    Growney JD,Clark JJ,Adelsperger J, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721724.
  • 111
    Gotlib J,Berube C,Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 28652870.
  • 112
    Gotlib J,DeAngelo DJ,George TI, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of a Fully Accrued Phase II Trial. In: American Society of Hematology Annual Meeting Abstracts.
  • 113
    Gotlib J,DeAngelo DJ,George TI, et al. Blood 2010; 116: 316.